ACRV CLO has 659 shares withheld for taxes

Acrivon Therapeutics, Inc. insider Mary Miller, the company’s Chief Legal Officer, reported a routine share withholding related to equity compensation.

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. insider Mary Miller, the company’s Chief Legal Officer, reported a routine share withholding related to equity compensation. On 01/17/2026, 659 shares of common stock were withheld at a price of $1.98 per share to cover mandatory tax withholding when her restricted stock units vested. After this transaction, she beneficially owned 33,896 shares of Acrivon common stock, held directly. This type of transaction does not represent an open-market sale but an automatic tax-related adjustment.

Insider Trade Summary

Exercise Price or Tax Liability: 659 shares

Exercise Price or Tax Liability 1 txn

Insider Miller Mary

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	659	$1.98	$1K

Holdings After Transaction: Common Stock — 33,896 shares (Direct)

Footnotes (1)

1. F1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ACRV Chief Legal Officer Mary Miller report?

Mary Miller reported that 659 shares of Acrivon Therapeutics common stock were withheld on 01/17/2026 to satisfy tax obligations upon vesting of restricted stock units.

Was the ACRV Form 4 transaction an open-market sale of shares?

No. The Form 4 states that the 659 shares were withheld by the issuer to meet mandatory tax withholding when restricted stock units vested, rather than being sold in the open market.

How many ACRV shares does Mary Miller own after this Form 4 transaction?

Following the reported transaction, Mary Miller beneficially owned 33,896 shares of Acrivon Therapeutics common stock, held directly.

What does transaction code "F" mean in the ACRV Form 4 filing?

Transaction code "F" indicates shares were used to pay tax withholding obligations upon the vesting of equity awards, such as restricted stock units.

What role does Mary Miller hold at Acrivon Therapeutics (ACRV)?

Mary Miller is identified in the filing as an officer of Acrivon Therapeutics, serving as the company’s Chief Legal Officer.

Does the ACRV insider transaction change Mary Miller’s ownership form?

No. The Form 4 shows her ownership remains direct (D) following the tax withholding transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 04:02 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Mary

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/17/2026		F(1)		659	D	$1.98	33,896	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.